SAN
DIEGO, July 26, 2022 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it
will release its second quarter 2022 financial and operating
results on Tuesday, August 9, 2022,
following the close of trading.
Halozyme will host a conference call on Tuesday, August 9, 2022 at 4:30 p.m. ET to
discuss the results. The dial-in numbers are (888) 330-2408 for
domestic callers and (240) 789-2703 for international callers. The
conference ID number is 89853. A live webcast and replay of the
conference call will be available online on the investor relations
section of the Halozyme Therapeutics corporate website
at www.halozyme.com.
About Halozyme
Halozyme is a biopharmaceutical company bringing disruptive
solutions to significantly improve patient experiences and outcomes
for emerging and established therapies. As the innovators of the
ENHANZE® technology with the proprietary enzyme rHuPH20,
Halozyme's commercially-validated solution is used to facilitate
the delivery of injected drugs and fluids in order to reduce the
treatment burden to patients. Having touched more than 600,000
patient lives in post-marketing use in five commercialized products
across more than 100 global markets, Halozyme has licensed its
ENHANZE® technology to leading pharmaceutical and
biotechnology companies including Roche, Baxalta, Pfizer, AbbVie,
Eli Lilly, Bristol-Myers Squibb, Alexion, argenx, Horizon
Therapeutics, ViiV Healthcare and Chugai Pharmaceutical.
Halozyme also develops, manufactures and commercializes, for
itself or with partners, drug-device combination products using its
advanced auto-injector technology that are designed to provide
commercial or functional advantages such as improved convenience
and tolerability, and enhanced patient comfort and adherence. The
Company has a commercial portfolio of proprietary products
including XYOSTED®, TLANDO™ and
NOCDURNA® and partnered commercial products and ongoing
product development programs with industry leading pharmaceutical
companies including Teva Pharmaceutical, Covis Pharma, Pfizer and
Idorsia Pharmaceuticals.
Halozyme is headquartered in San
Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka
is also the site of its operations facility.
For more information visit www.halozyme.com and
connect with us on LinkedIn and Twitter.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@antarespharma.com
Dawn Schottlandt / Claudia Styslinger
Argot Partners
212-600-1902
Halozyme@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/halozyme-to-report-second-quarter-2022-financial-and-operating-results-301593154.html
SOURCE Halozyme Therapeutics, Inc.